Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Education
Participant Experiences From Chronic Administration Of A Multivitamin Versus Placebo On Subjective Health And Wellbeing: A Double-Blind Qualitative Analysis Of A Randomised Controlled Trial, Jerome Sarris, Katherine H M Cox, David A. Camfield, Andrew Scholey, Con Stough, Erin Fogg, Marni Kras, David J. White, Avni Sali, Andrew Pipingas
Participant Experiences From Chronic Administration Of A Multivitamin Versus Placebo On Subjective Health And Wellbeing: A Double-Blind Qualitative Analysis Of A Randomised Controlled Trial, Jerome Sarris, Katherine H M Cox, David A. Camfield, Andrew Scholey, Con Stough, Erin Fogg, Marni Kras, David J. White, Avni Sali, Andrew Pipingas
Faculty of Social Sciences - Papers (Archive)
Background While many randomised controlled trials have been conducted on multivitamins, to our knowledge no qualitative research exploring the subjective experience of taking a multivitamin during a clinical trial has been reported. Methods Semi-structured and open-ended written questions were incorporated into a 16-week double-blind, randomised, placebo-controlled, parallel groups trial of once-daily multivitamin administration. At the final study visit (week 16), three open-ended questions were posed to elucidate any positive, negative or unusual experiences from taking either the multivitamin or matched placebo. Qualitative thematic analysis was undertaken by researchers who were blind as to treatment condition of participants, and triangulation (independent …
Effects Of Δ9-Tetrahydrocannabinol Administration On Human Encoding And Recall Memory Function: A Pharmacological Fmri Study, Matthijs G. Bossong, Gerry Jager, Hendrika H. Van Hell, Lineke Zuurman, J Martijn Jansma, Mitul A. Mehta, Joop M. A Van Gerven, Rene S. Kahn, Nick F. Ramsey
Effects Of Δ9-Tetrahydrocannabinol Administration On Human Encoding And Recall Memory Function: A Pharmacological Fmri Study, Matthijs G. Bossong, Gerry Jager, Hendrika H. Van Hell, Lineke Zuurman, J Martijn Jansma, Mitul A. Mehta, Joop M. A Van Gerven, Rene S. Kahn, Nick F. Ramsey
Faculty of Social Sciences - Papers (Archive)
Deficits in memory function are an incapacitating aspect of various psychiatric and neurological disorders. Animal studies have recently provided strong evidence for involvement of the endocannabinoid (eCB) system in memory function. Neuropsychological studies in humans have shown less convincing evidence but suggest that administration of cannabinoid substances affects encoding rather than recall of information. In this study, we examined the effects of perturbation of the eCB system on memory function during both encoding and recall. We performed a pharmacological MRI study with a placebo-controlled, crossover design, investigating the effects of Δ9-tetrahydrocannabinol (THC) inhalation on associative memory-related brain function in 13 …
Initial Severity And Antidepressant Benefits: A Meta-Analysis Of Data Submitted To The Food And Drug Administration, Irving Kirsch, Brett J. Deacon, Tania B. Huedo-Medina, Alan Scoboria, Thomas J. Moore, Blair T. Johnson
Initial Severity And Antidepressant Benefits: A Meta-Analysis Of Data Submitted To The Food And Drug Administration, Irving Kirsch, Brett J. Deacon, Tania B. Huedo-Medina, Alan Scoboria, Thomas J. Moore, Blair T. Johnson
Faculty of Social Sciences - Papers (Archive)
Background: Meta-analyses of antidepressant medications have reported only modest benefits over placebo treatment, and when unpublished trial data are included, the benefit falls below accepted criteria for clinical significance. Yet, the efficacy of the antidepressants may also depend on the severity of initial depression scores. The purpose of this analysis is to establish the relation of baseline severity and antidepressant efficacy using a relevant dataset of published and unpublished clinical trials. Methods and Findings: We obtained data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of the four new-generation antidepressants for which …